Beam Therapeutics (BEAM)
(Delayed Data from NSDQ)
$23.41 USD
+0.47 (2.05%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $23.41 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Beam Therapeutics Inc. (BEAM) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$50.36 | $80.00 | $23.00 | 119.53% |
Price Target
Based on short-term price targets offered by 14 analysts, the average price target for Beam Therapeutics Inc. comes to $50.36. The forecasts range from a low of $23.00 to a high of $80.00. The average price target represents an increase of 119.53% from the last closing price of $22.94.
Analyst Price Targets (14)
Broker Rating
Beam Therapeutics Inc. currently has an average brokerage recommendation (ABR) of 1.88 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 16 brokerage firms. The current ABR compares to an ABR of 1.88 a month ago based on 16 recommendations.
Of the 16 recommendations deriving the current ABR, nine are Strong Buy, representing 56.25% of all recommendations. A month ago, Strong Buy represented 56.25%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 9 | 9 | 8 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 7 | 7 | 7 | 7 | 7 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.88 | 1.88 | 1.88 | 1.88 | 1.93 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/11/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/7/2024 | Cantor Fitzgerald & Co | Rick Bienkowski | Hold | Hold |
8/7/2024 | Not Identified | Not Identified | Hold | Hold |
8/6/2024 | Wedbush Securities | David M Nierengarten | Strong Buy | Strong Buy |
8/6/2024 | Wells Fargo Securities | Yanan Zhu | Strong Buy | Strong Buy |
7/23/2024 | H.C. Wainwright & Co. | Patrick Trucchio | Not Available | Strong Buy |
7/9/2024 | Not Identified | Not Identified | Hold | Hold |
5/7/2024 | SVB Securities | Mani Foroohar | Hold | Hold |
4/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/27/2024 | BMO Capital Markets | Kostas Biliouris | Strong Buy | Strong Buy |
2/27/2024 | Guggenheim Securities | Debjit Chattopadhyay | Strong Buy | Strong Buy |
2/27/2024 | William Blair | Sami Corwin | Strong Buy | Strong Buy |
2/8/2024 | Not Identified | Not Identified | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.88 |
ABR (Last week) | 1.88 |
# of Recs in ABR | 16 |
Average Target Price | $50.36 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 73 of 252 |
Current Quarter EPS Est: | -1.13 |
BEAM FAQs
Beam Therapeutics Inc. (BEAM) currently has an average brokerage recommendation (ABR) of 1.88 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 16 brokerage firms.
The average price target for Beam Therapeutics Inc. (BEAM) is $50.36. The current on short-term price targets is based on 9 reports.
The forecasts for Beam Therapeutics Inc. (BEAM) range from a low of $23 to a high of $80. The average price target represents a increase of $115.12 from the last closing price of $23.41.
The current UPSIDE for Beam Therapeutics Inc. (BEAM) is 115.12%
Based on short-term price targets offered by 14 analysts, the average price target for Beam Therapeutics Inc. comes to $50.36. The forecasts range from a low of $23.00 to a high of $80.00. The average price target represents an increase of 119.53% from the last closing price of $22.94.